This federal Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), is focused on developing a novel siRNA-based treatment approach to enhance Gsα-mediated hormone signaling. The $449,636 award, granted on July 23, 2025, supports research at The General Hospital Corporation (Massachusetts General Hospital) to investigate a strategy for restoring...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $172,060 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on the role of the unfolded protein response (UPR) in the pathogenesis of non-alcoholic steatohepatitis (NASH). The research aims to understand the mechanism of UPR loss...
This federal Project Grant award of $136,230 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), funded under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support research at The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate the role of salt-inducible kinases (SIKs) in regulating vitamin D metabolism and their potential therapeutic application for mineral and bone...
The National Institute of General Medical Sciences (NIGMS) awarded a $453,750 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the project "Revealing the Crosstalk Between One Carbon Metabolism, SAM Availability and Chromatin Methylation". This 5-year grant, effective June 1, 2025, will support MGH's innovative research investigating how cellular...
This Project Grant award from the National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) supports research to integrate genetic and socio-environmental factors to predict disease progression. The $138,499 award to The General Hospital Corporation (doing business as Massachusetts General Hospital) aims to develop statistical models that leverage genetic, longitudinal healthcare, and socio-environmental data to enhance precision medicine for 16 exemplar disease...
This Project Grant award of $1,350,094 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award supports advanced biomedical research by The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate metabolites, metabolic pathways, and the risk of Crohn's disease. The performance period for this award is from July 1, 2025 to June 30, 2029. As a leading academic medical...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $1,000,100 Cooperative Agreement to The General Hospital Corporation (doing business as Massachusetts General Hospital) on September 1, 2024. The award will fund a consortium to study gut-brain communication in Parkinson's disease (PD). Key objectives include: Contributing PD patients and healthy controls to a...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $800,005 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on the structural basis and functional impacts of genetic variants in G-protein coupled receptors (GPCRs) associated with autoimmune diseases. The project aims to: 1) define the structural basis for impaired...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) under CFDA Program 93.859 Biomedical Research and Research Training provides $338,889.00 to investigate the structure and enzymology of the glucose-6-phosphatase catalytic subunit 1 (G6PC1), an integral membrane protein that plays a key role in glucose metabolism. The 5-year research project, led by Vanderbilt University, aims to use biophysical and computational techniques to establish the...
This $370,575 project grant from the National Institutes of Health National Cancer Institute Cancer Biology Research program (CFDA 93.396) will fund research at the University of Cincinnati investigating the molecular mechanisms of growth in pancreatic cancer with GNAS mutations. The grant supports studies from August 1, 2022 to July 31, 2027 to further the understanding of the oncogenic functions of mutant GNAS and its downstream signaling pathways. Specifically, the research will illuminate...
This Project Grant award of $1,107,090, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research, supports research at The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate the regulation of G protein alpha subunit (Gsα) expression and its role in hormone signaling.
The research aims to elucidate the mechanisms by which GNAS gene methylation controls allelic Gsα expression, and how this impacts hormone signaling in specific tissues. The project will utilize human embryonic stem cell and induced pluripotent stem cell models to study the relationship between GNAS methylation, Gsα expression, and hormone resistance associated with pseudohypoparathyroidism type 1B. The findings are expected to contribute to a deeper understanding of the disease mechanisms underlying end-organ resistance to parathyroid hormone and thyroid-stimulating hormone.